Strategics join $35M A round for Surface Oncology
Cancer immunotherapy play Surface Oncology Inc. (Cambridge, Mass.) raised $35 million in a series A round led by existing investor Atlas Venture. New investors Fidelity Biosciences; Lilly Ventures; New Enterprise Associates (NEA); Amgen Ventures; and Novartis Institutes for BioMedical Research (NBIR) joined the round. Also participating as an investor was Elliott Sigal, former head of R&D at Bristol-Myers Squibb Co. (NYSE:BMY).
Surface is developing undisclosed preclinical programs against cancer immunotherapy targets outside of checkpoint inhibition that aim to improve the effectiveness of antigen presentation, block activity of suppressor cells in the tumor microenvironment, or counter the impact of specific undisclosed cytokines and metabolites. The company expects to select candidates for preclinical development this year. ...